This site is intended for healthcare professionals
DNA AI generated image
  • Home
  • /
  • Medical Education
  • /
  • Molecular biomarker testing for prostate cancer
  • /
  • Podcast 3: Molecular testing techniques for patien...

Podcast series: Molecular biomarker testing for prostate cancer

These podcasts have been developed and funded by AstraZeneca and are intended for healthcare professionals only.
Last updated: 17th May 2024
Published:17th May 2024

Listen to this podcast series on metastatic castration-resistant prostate cancer (mCRPC), featuring insights from leading experts on the current molecular testing landscape and perspectives on the predictive value of HRR/BRCA mutation (BRCAm) status.

Podcast 3: Molecular testing techniques for patients with mCRPC

Dr Alessia Cimadamore (Italy), Dr Niven Mehra (the Netherlands), Dr Pasquale Rescigno (UK) and Dr Michelle Shiller (USA) share their experiences from across the globe on the evolving diagnostic methods for patients with mCRPC.

Meet the experts

Dr Alessia Cimadamore.pngDr Alessia Cimadamore

Dr Alessia Cimadamore is a pathologist known for her work in prostate cancer. She is currently an assistant professor at the University of Udine, Italy, where she focuses on genitourinary tumours.

Disclosures: Financial support from Amgen, AstraZeneca, and MSD.


Dr Niven Mehra.pngDr Niven Mehra

Dr Niven Mehra is a medical oncologist specialising in prostate cancer. He is an associate professor and clinician at the Radboud University Medical Center, Nijmegen, the Netherlands. His work primarily focuses on understanding the genetic landscape of metastatic prostate cancer to develop new therapeutic strategies.

Disclosures: Financial support from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb Foundation, Janssen-Cilag, MSD Oncology, and Pfizer.

Dr Pasquale Rescigno.pngDr Pasquale Rescigno

Dr Pasquale Rescigno is a medical oncologist with a focus on genitourinary tumours. He is a clinical senior lecturer and honorary consultant at Newcastle University, UK. His work involves the development of clinical trials, aiming to further understand prostate cancer and enhance patient care.

Disclosures: Financial support from AstraZeneca, Gilead, Ipsen, Janssen, MSD, Pfizer, and Prostate Cancer Foundation.

Dr Michelle Shiller.pngDr Michelle Shiller

Dr Michelle Shiller is a pathologist specialising in molecular genetic pathology. She is a member of the Precision Medicine Institute’s advisory committee, working on molecular diagnostics and genetic testing at the Baylor University Medical Center, Dallas, Texas, USA.

Disclosures: Financial support from Amgen, Astellas, AstraZeneca, Lilly, Merck, Mirati Therapeutics, Pfizer, and Takeda.

Welcome:

Developed by EPG Health for Medthority with content provided by AstraZeneca in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content [Z4-61967, March 2024 | Recording Z4-62403, March 2024].